AKUMS Q2 : CONS NET PROFIT UP 168.3% AT RS 10.97 CR (YOY), UP 13.5% (QOQ). STRONG (ON 1ST LOOK)

• Revenue up 31.9% at ₹1,342.39 Cr (YoY), up 15.1% (QoQ). • EBITDA up 106% at ₹194.73 Cr (YoY); margins 14.5% vs 9.3% (YoY), 15.0% (QoQ). • CDMO revenue up 38.6% at ₹1,114.87 Cr (YoY); API revenue down 35.3% at ₹28.77 Cr (YoY). • WOS Pure and Cure Healthcare completed acquisition of OriGaine India manufacturing business for ₹56 Cr cash. • Caution: ₹156.02 Cr tax demand for block period 2018-2025; ₹10.97 Cr deposited under protest.

Akums Drugs and Pharmaceuticals Limited

Open attachment

← Back to feed